Need Help? Contact Us.

Enquire now


Product Description

For determination of Cartilage Oligomeric Matrix Protein (COMP) in human serum. Results are to be used as an aid in the prognosis and monitoring of cartilage degradation in conditions such as rheumatoid arthritis and osteoarthritis.

  • Improved assay for determination of human cartilage oligomeric matrix protein (COMP)
  • Accurate and precise measurement of COMP
  • No observed interference from other thrombospondins
  • Part of a complete assay panel supporting clinical bone and cartilage research
    1. Posey KL, Coustry F, Hecht JT. Cartilage oligomeric matrix protein: COMPopathies and beyond. Matrix Biol. 2018 Oct;71-72:161-173.
    2. Morozzi G, Fabbroni M, Bellisai F, Pucci G, Galeazzi M. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments. Ann N Y Acad Sci. 2007 Jun;1108:398-407.
    3. Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers. 2005 Nov;10 Suppl 1:S44-9.
    4. Ritter SY, Collins J, Krastins B, Sarracino D, Lopez M, Losina E, Aliprantis AO. Mass spectrometry assays of plasma biomarkers to predict radiographic progression of knee osteoarthritis. Arthritis Res Ther. 2014 Oct 7;16(5):456
    5. Wollheim FA. Predictors of joint damage in rheumatoid arthritis. APMIS. 1996 Feb;104(2):81-93.
    6. Dénarié D, Constant E, Thomas T, Marotte H. Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? Mediators Inflamm. 2014;2014:537324.

Add to Enquiry Basket



Related Products

Assays Certification Platform Clinical Area Portfolio RUO/IVD
Urine CartiLaps® (CTX-II) EIA 510 (k) exemptCE Marked Cartilage Markers Endocrinology IVD
Serum Pre-Clinical CartiLaps® (CTX-II) EIA Research Use Only Cartilage Animal Research RUO
This site is registered on as a development site.